Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy
To investigate the oncological impact of incidental prostate cancer (iPCa) found during radical cystoprostatectomy (RCP) on overall survival (OS) prognosis of urothelial carcinoma of the bladder (BCa).
Patients and methods
A total of 122 RCP cases resected between 2002 and 2012 at our center were included for study. Survival of BCa patient was compared using the Kaplan–Meier method and the log-rank test. Cox proportional hazards regression models were used to analyze the impact of iPCa on the 5-year overall mortality of BCa patients after RCP.
Among the 122 BCa cases that underwent RCP, 38 cases (31.1%) had iPCa, in which, 17 cases (44.7%) were identified as clinically significant iPCa (csPCa). BCa patients with iPCa were older (71 vs 64 years, p = 0.004) and had higher preoperative PSA level (3.1 ng/mL vs 1.4 ng/mL, p = 0.017) when compared to those without iPCa. Cases with iPCa showed a more favorable 5-year OS than cases without iPCa, although this difference did not reach statistical significance (p = 0.219). When excluding the higher risk cases with Gleason score (GS) ≥ 4 + 3 and/or preoperative PSA > 10 ng/mL, BCa patients with iPCa showed a significantly longer OS than cases without iPCa on univariate analysis (p = 0.044), but not on multivariate analysis (p = 0.125).
Our results demonstrated that the frequent findings of low-risk iPCa in BCa patients could indicate the potential possibility of shared pathogenesis pathways between iPCa and BCa. Future study with a larger cohort is warranted to validate this result.
KeywordsBladder cancer Incidental prostate cancer Cystoprostatectomy Prognosis Androgen receptor
Urothelial carcinoma of the bladder
Muscle-invasive bladder cancer
Incidental prostate cancer
Clinical significant iPCa
Clinical insignificant iPCa
Digital rectal examination
Soft-tissue surgical margin
Androgen deprivation therapy
Compliance with ethical standards
Conflict of interest
All the authors declare that there is no conflict of interest.
All procedures involving human participants were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and subsequent amendments or comparable ethical standards.
- 2.Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1):45–57. https://doi.org/10.1016/j.eururo.2012.08.009 PubMedGoogle Scholar
- 3.Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G (2017) Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: a systematic review and meta-analysis of 13,140 patients. J Urol 197(2):385–390. https://doi.org/10.1016/j.juro.2016.08.088 PubMedGoogle Scholar
- 4.Wolters T, Montironi R, Mazzucchelli R, Scarpelli M, Roobol MJ, van den Bergh RC, van Leeuwen PJ, Hoedemaeker RF, van Leenders GJ, Schroder FH, van der Kwast TH (2012) Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate 72(1):108–115. https://doi.org/10.1002/pros.21415 PubMedGoogle Scholar
- 7.Buse S, Hofner T, Muller SC, Hermann E, Wieland WF, May M, Stief CG, Bastian PJ, Hohenfellner M, Haferkamp A (2013) Characterization and risk stratification of prostate cancer in patients undergoing radical cystoprostatectomy. Int J Urol 20(9):866–871. https://doi.org/10.1111/iju.12073 PubMedGoogle Scholar
- 8.Thomas C, Giesswein A, Hainz M, Stein R, Rubenwolf P, Roos FC, Neisius A, Nestler S, Hampel C, Jager W, Wiesner C, Thuroff JW (2015) Concomitant Gleason Score %3e/= 7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy. Int Urol Nephrol 47(11):1789–1796. https://doi.org/10.1007/s11255-015-1110-1 PubMedGoogle Scholar
- 9.Gakis G, Rink M, Fritsche HM, Graefen M, Schubert T, Hassan F, Chun FK, Brummeisl W, Fisch M, Burger M, Stenzl A, Renninger M (2016) Prognostic significance of incidental prostate cancer at radical cystoprostatectomy for bladder cancer. Urol Int 97(1):42–48. https://doi.org/10.1159/000443239 PubMedGoogle Scholar
- 11.Malte R, Kluth LA, Kaushik D, Boorjian SA, Abufaraj M, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz PI, Roupret M, Briganti A, Scherr DS, Shariat SF, Seebacher V (2017) Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. Eur J Surg Oncol 43(11):2193–2199. https://doi.org/10.1016/j.ejso.2017.08.013 PubMedGoogle Scholar
- 12.Kaelberer JB, O'Donnell MA, Mitchell DL, Snow AN, Mott SL, Buatti JM, Smith MC, Watkins JM (2016) Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival. Prostate Int 4(3):107–112. https://doi.org/10.1016/j.prnil.2016.06.002 PubMedGoogle Scholar
- 15.Moschini M, Shariat SF, Freschi M, Soria F, Abufaraj M, Gandaglia G, Dell'Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R (2017) Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer. Urol Int 98(3):290–297. https://doi.org/10.1159/000454736 PubMedGoogle Scholar
- 20.Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M (2017) Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5alpha-reductase inhibitor. J Urol 197(2):308–313. https://doi.org/10.1016/j.juro.2016.08.006 PubMedGoogle Scholar
- 22.Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, Ueki T, Udagawa K, Kitami K, Moriyama M, Miyoshi Y, Tsuchiya F, Ikeda I, Kobayashi K, Sato M, Morita S, Noguchi K, Uemura H (2014) Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5(24):12665–12674. https://doi.org/10.18632/oncotarget.2851 PubMedGoogle Scholar
- 26.Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99(7):558–568. https://doi.org/10.1093/jnci/djk113 PubMedGoogle Scholar
- 31.Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol 71(6):952–960. https://doi.org/10.1016/j.eururo.2016.12.020 PubMedGoogle Scholar